A Randomized Placebo-controlled Double Blind Trial of Liraglutide 3 mg [Saxenda] on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With Polycystic Ovary Syndrome (PCOS)
Phase of Trial: Phase III
Latest Information Update: 26 Oct 2018
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms SAXAPCOS
- 26 Sep 2018 Status changed from not yet recruiting to recruiting.
- 24 Sep 2018 Planned End Date changed from 15 Oct 2020 to 15 Nov 2020.
- 24 Sep 2018 Planned primary completion date changed from 8 Sep 2020 to 8 Oct 2020.